Former Silver Lake Managing Director brings extensive experience advising large, established technology businesses

RALEIGH, N.C., Oct. 29, 2026 /PRNewswire/ -- Bandwidth Inc. (NASDAQ: BAND), a leading global cloud communications company, today announced that its board of directors has elected Chip Schroeder as a director. His election is effective Oct. 28, 2026, and brings Bandwidth's board to six members, four of whom are independent.

Schroeder has extensive investment and board experience with large, established technology and technology-enabled businesses across a range of verticals, including digital infrastructure, fintech, software and entertainment. He spent more than a decade at Silver Lake in the Menlo Park and New York offices, rising to managing director and working closely with portfolio company leadership teams advising on strategic growth, capital allocation and long-term value creation.

During his time at Silver Lake, Schroeder served on the boards of directors of Blackhawk Network, Cast & Crew, Clubessential Holdings, Oak View Group and Shadowbox Studios, among others. He graduated from Stanford University with a B.A. in History, where he competed on the varsity rowing team. He is currently active in investing, Christian ministry and biblical studies at Reformed Theological Seminary in Orlando, Fla.

"Chip brings deep experience in go-to-market, corporate strategy and capital markets, built over more than a decade working with the leaders of large, growing technology businesses across verticals, business models and market cycles," said David Morken, Bandwidth's Co-founder, Chairman and CEO. "Just as important, he appreciates Bandwidth's unique, mission-driven culture. I'm delighted to welcome him to the board as we continue to scale."

"What I've enjoyed most throughout my career is working alongside leadership teams as they build and grow substantial businesses," said Schroeder. "Bandwidth is at an exciting stage in its growth, serving some of the world's largest companies as super intelligence opens a new chapter for communications. I'm also impressed by Bandwidth's distinctive culture and values, which I consider essential to building a successful business for the long term. I'm looking forward to working with David and the team."

About Bandwidth Inc.

Bandwidth Inc. (NASDAQ: BAND) is a leading global cloud communications company that helps enterprises deliver exceptional experiences through voice calling, text messaging and emergency services. Our solutions and our Communications Cloud, covering ~70 countries and 90 percent of global GDP, are trusted by all the leaders in unified communications and cloud contact centersâincluding Amazon Web Services (AWS), Cisco, Google, Microsoft, RingCentral, Zoom, Genesys and Five9âas well as Global 2000 enterprises and SaaS builders like Docusign, Uber and Yosi Health. As a founder of the cloud communications revolution, we are the first and only global Communications Platform-as-a-Service (CPaaS) to offer a unique combination of composable APIs, super intelligence capabilities, owner-operated network and broad regulatory experience. Our award-winning support teams help businesses around the world transform their communications every day.

SOURCE Bandwidth Inc.

Share this article

Update delivers a fluid, modernized experience, seamless dual-screen multitasking and automated credential maintenance

CHICAGO, Oct. 29, 2026 /PRNewswire/ -- Keeper Security, the leading zero-trust and zero-knowledge identity security platform, today announced a major update to its iOS application with the release of version 18.1. The latest release introduces a completely redesigned vault interface utilizing Liquid Glass, support for Apple's new dual-screen iPhone Duo and powerful automation features that simplify credential management on the go. Representing one of the most significant UI overhauls in the company's history, the update bridges enterprise-grade security to business and individual users alike, with an exceptionally sleek and modern mobile experience.

As mobile devices increasingly function as primary tools for enterprise operations and privileged access management, maintaining strict zero-trust identity controls without sacrificing usability has become a critical security priority. The release of version 18.1 for iOS expands Keeper's commitment to providing intuitive, high-performance security tools that allow organizations to govern human and machine access seamlessly from any device, while bringing the same enterprise-grade security architecture and user experience to consumers.

"Friction is the enemy of enterprise security," said Craig Lurey, CTO and Co-founder of Keeper Security. "We engineered this update to fully leverage Apple's Liquid Glass design system and the dual-screen architecture of the iPhone Duo, stripping away navigational complexity. The result is a highly responsive, intuitive interface that accelerates access for our users while maintaining the uncompromising zero-knowledge encryption our platform is built on."

Next-Generation Mobile Identity Management

Version 18.1 of the Keeper mobile app for iOS brings key enhancements to the Keeper platform:

- iPhone Duo Multi-Tasking Optimization: Fully optimized for Apple's new folding-screen hardware, Keeper's Vault interface expands dynamically when the device is open. Users can navigate folders and view detailed record entries side by side, streamlining complex administrative workflows. The application smoothly transitions back to a standard, single-screen layout when closed.

- Liquid Glass User Interface and Vault Streamlining: Rebuilt using Apple's Liquid Glass design, the app delivers a fluid, modernized visual experience. Essential tools like search, Keeper's Security Audit and two-factor codes have moved to a dedicated bottom toolbar for faster access, while account settings are now centralized in an intuitive avatar menu. A new floating action button and swipeable product tour help users easily discover and navigate helpful features.

- Smart Password Generation and Autofill: KeeperFill now suggests and injects strong, unique passwords directly into iOS system prompts when creating or resetting accounts, seamlessly updating the vault in the background.

- Automated Credential Maintenance: Keeper quietly processes site-reported changes in the background. If a website signals that a passkey was revoked, or a password is no longer active, Keeper automatically updates or clears the vault entry without requiring user intervention.

- Clearer Security Audits and Connection Status: The Security Audit screen has been redesigned to provide plain-language account health evaluations and now loads significantly faster for large vaults. Users also now have distinct, real-time visual indicators showing when the app is syncing or operating offline.

- Advanced Sharing and Folder Controls: Users can now easily share multiple files to Keeper directly from the iOS Activity View. For enterprise users, new administrative controls allow for moving nested shared folders and explicitly denying access to specific folders.

Governing Identity at Machine Speed

While version 18.1 of the Keeper app for iOS dramatically improves the everyday user experience, it operates on a foundation built for modern enterprise defense. With the rapid adoption of AI agents, Non-Human Identities (NHIs) and complex multi-cloud environments, modern cyber attacks increasingly target identity workflows rather than perimeter software flaws.

Keeper's identity security platform is the control plane for all identities including humans, machines, NHIs and AI agents. With the proliferation of AI agents in the enterprise and the challenges faced by IT teams to manage them, Keeper determines whether and how AI is allowed to act inside the enterprise.

Keeper's zero-trust and zero-knowledge architecture ensures that all encryption and decryption operations occur locally on the user's device using private keys that never leave the endpoint. Whether managing privileged cloud infrastructure, database connections, API secrets or daily user credentials, Keeper provides a unified, auditable access plane across every desktop, mobile device and automated workflow.

The latest version of the Keeper mobile app is available now on the Apple App Store. To learn more about Keeper's zero-trust identity security platform, visit keepersecurity.com.

About Keeper Security

Keeper Security is the leading zero-trust and zero-knowledge identity security solution, trusted by millions of people and thousands of organizations globally. KeeperPAM® is Keeper's privileged access management platform that unifies password and passkey management, secrets management, privileged session management and endpoint privilege management in a single cloud-native platform, protected with quantum-resistant encryption. KeeperAI delivers real-time, AI-native threat detection across every privileged session. As AI agents proliferate and identity becomes the defining attack surface, Keeper governs access for humans, machines, non-human identities and AI agents, serving as the unified control plane for access, compliance and visibility across the enterprise. For more information, visit KeeperSecurity.com.

Learn more: KeeperSecurity.com

Follow Keeper: Facebook Instagram LinkedIn X YouTube TikTok

Media Contact

Christian Morley

ICR for Keeper Security

[email protected]

SOURCE Keeper Security

Share this article

NATIVE COLLEGE ATHLETES DISCOVER BASKETBALL MEANS MORE THAN A GAME IN NEW DOCUMENTARY "MEDICINE BALL"

SAINT PAUL, Minn., Oct. 29, 2026 /PRNewswire/ -- A compelling new documentary exploring the power of sport, cultural pride, and personal journeys of Native college athletes is set to premiere on PBS during Native American Heritage Month. Directed by Dakota/Diné filmmaker Leya Hale, Medicine Ball follows Lexus Redthunder and LeRoy Staples Fairbanks IV as they navigate college life and basketball at the University of Minnesota Morris, located on the site of a former Native boarding school. Their journeys reveal how basketball became a powerful symbol of resilience, hope, and pride â a way to carry forward culture, build community, and create joy amidst adversity.

"Medicine Ball is about more than basketball. It's about identity, belonging, and the ways Native young people carry history while creating their own paths forward," said Hale. "I hope audiences see the strength, joy, and cultural pride that live alongside the harder parts of this story."

Medicine Ball airs on November 9 at 8 pm CST. To learn more about the documentary, visit MinnesotaPBS.org/medicine-ball-film.

About The Director

Leya Hale (Sisseton Wahpeton Dakota and Diné) was named the 2026 recipient of the Minnesota Filmmaker Award at the Zeitgeist Minnesota Film Festival. The award honors Minnesota-tied filmmakers for creativity, craftsmanship, and storytelling. She is a multiple regional Emmy Awardâwinning producer for Minnesota PBS and is known for nationally broadcasted films The People's Protectors (PBS), Bring Her Home (PBS), and The Electric Indian (APT).

About The Players

Lexus Redthunder is an advocate and emerging leader from the Sisseton Wahpeton Oyate. A graduate of the University of Minnesota Morris, she was a standout player for the Cougars women's basketball team and earned degrees in Native American and Indigenous Studies and Political Science. She is recognized for her leadership, community involvement, and commitment to uplifting Native youth. Lexus is featured in the PBS documentary Medicine Ball, which explores the experiences of Native student-athletes and the lasting impact of Indian boarding school history. Her connection to the story is deeply personal. Her great grandmother attended the Morris Industrial School for Indians, once located on the present-day UMN Morris campus.

LeRoy Staples-Fairbanks IV is a student-athlete and emerging community leader from the Leech Lake Band of Ojibwe. A senior at the University of Minnesota Morris, he competes on both the Cougars basketball and golf teams while pursuing a degree in Sport Management. LeRoy is proud of his Ojibwe heritage and encourages students from reservation communities to pursue higher education and athletics.

SOURCE Minnesota PBS

Share this article

STARTRADER Begins Second Season as Official Partner of the NBA

The new season builds on STARTRADER's first-year activations, including the STAR Trading League, as the multi-year collaboration with the NBA continues.

DUBAI, UAE, Oct. 29, 2026 /PRNewswire/ -- STARTRADER is building on its first season as the Official Partner of the NBA, with plans to further engage its community throughout the 2026-27 NBA season, which tipped off on Oct. 20. STARTRADER will continue to have a presence throughout the season through in-arena backdrops, broadcast-visible placements, select league media platforms and live events.

Since announcing its collaboration with the NBA in January 2026, STARTRADER has expanded its activities beyond brand presence to include the STAR Trading League, a basketball-inspired trading tournament created for the STARTRADER community.

"Our first season working with the NBA showed us how this collaboration could extend beyond brand visibility. Through the STAR Trading League, we turned that connection into an experience our own community could participate in. The next chapter is about going further, creating more meaningful ways for audiences across our markets to engage with the NBA."

â Peter Karsten, CEO, STARTRADER

The 2026-27 NBA season tipped off with three games on Oct. 20 and will feature Emirates NBA Cup action beginning Oct. 30, regular-season games in Paris and Manchester in January, and NBA All-Star 2027 in Phoenix from Feb. 19-21. These events are among the major moments on the NBA calendar throughout the season.

For STARTRADER, the new season represents an opportunity to build on the foundations established during its first year working with the NBA. Basketball's demands for preparation, adaptability and performance under pressure reflect the company's pillars of Strength, Trust, Ambition and Resilience, providing a connection between the sport and STARTRADER's brand values.

About STARTRADER

STARTRADER is a global multi-asset broker empowering retail and institutional partners to access global markets through platforms including MetaTrader, STARTRADER APP and STAR Copy.

STARTRADER operates through entities licensed and regulated by authorities including CMA, ASIC, FSCA, FSA and FSC, combining strong governance with a client-first approach and a commitment to transparency, reliability and long-term growth.

SOURCE STARTRADER

Share this article

Third Quarter 2026 Highlights

(Comparisons are year-over-year ("YoY"), unless otherwise noted)

- Sales of $941 million; net earnings of $126 million and diluted earnings per share (EPS) of $0.93

- North America segment sales of $761.6 million increased 3% driven by Leonard Valve acquisition sales, 13% boiler sales growth and the benefits of pricing actions, partially offset by lower residential water heater volumes

- Rest of World segment sales of $192.8 million decreased 7%, reflecting continued weakness in China's consumer appliance market

- Year-to-date operating cash flow was $429 million and free cash flow increased 4% to $396 million

- Concluded China strategic assessment with definitive agreements, announced October 27, under which CPE will acquire an 81% interest in the Company's China business; with A. O. Smith retaining a 19% stake and long-term brand license

- 2026 full year guidance has been updated to exclude the China business for all of 2026:

- Net sales growth, excluding China, of approximately 4%

- Adjusted EPS¹, excluding China, of between $3.42 and $3.52

MILWAUKEE, Oct. 29, 2026 /PRNewswire/ -- Global water technology company A. O. Smith Corporation ("A. O. Smith" or "the Company") (NYSE: AOS) today announced its third quarter 2026 results.

Key Financial Metrics

Third Quarter

(in millions, except per share amounts)

"Disciplined execution across our businesses remained a priority in the third quarter as we navigated persistent inflationary pressures, softer residential water heater demand in North America, and ongoing market challenges in China," said Steve Shafer, chairman and chief executive officer. "Our teams adapted to changing market conditions, managed costs and stayed focused on meeting our customers' needs. Supported by our leading market positions and financial strength, we believe we remain well positioned to address near-term headwinds and deliver long-term, profitable growth."

"Separately, earlier this week we announced definitive agreements with CPE to acquire an 81% interest in our China business," Shafer continued. "Our team in China has built a leading premium brand over more than three decades, and CPE is well positioned to lead that business forward. For A. O. Smith, this transaction completes our strategic assessment and enables us to focus our capital and resources on our highest-return opportunities and sustainable value creation. At the same time, our retained 19% stake and long-term brand license give our shareholders the opportunity to benefit from future growth in China under CPE's leadership."

Segment-level Performance

North America

Third quarter sales increased 3% to $761.6 million, driven by higher boiler volumes, pricing benefits and a $15 million sales contribution from Leonard Valve, acquired in January 2026, partially offset by lower residential water heater volumes. Excluding Leonard Valve, organic sales increased 1%.

Segment earnings were $179.9 million, and segment margin was 23.6% in the third quarter of 2026, compared to segment earnings of $179.7 million and segment margin of 24.2% in the same period of 2025. The 60-basis-point decline in segment margin was primarily due to lower residential water heater volumes and higher input costs, including steel and freight, more than offsetting the benefits of higher boiler volumes, International Emergency Economic Powers Act (IEEPA) tariff refunds, the benefits of pricing actions and the earnings contribution from Leonard Valve.

Rest of World

Rest of World sales of $192.8 million decreased 7% compared to the prior year period and included a favorable currency translation impact of $5 million primarily related to sales in China. China sales decreased 17% in local currency, reflecting continued weak consumer demand and disruption related to the recently concluded strategic assessment process.

Segment earnings were $10.5 million, and segment margin was 5.4% in the third quarter of 2026, compared to segment earnings of $15.4 million and segment margin of 7.4% in the same period of 2025. The lower segment earnings and segment margin compared to the prior year were primarily due to lower China sales volumes, partially offset by continued cost management.

Announced Sale of 81% Interest in China Business

On October 27, 2026, the Company announced definitive agreements with CPE, a leading alternative asset manager, to acquire an 81% interest in A. O. Smith's China business. A. O. Smith will retain a 19% stake and enter into a long-term brand license agreement, both of which allow it to participate in the business's future growth. The transaction values the China business at approximately $400 million on a cash-free, debt-free basis, before taking into account the long-term brand licensing royalty stream. The total value, including the net present value of the ongoing licensing economics payable to A. O. Smith over the multi-decade period, is expected to exceed $500 million. In addition, the transaction structure will enable A. O. Smith to repatriate approximately $80 million in cash that is currently being held in China. Consistent with its commitment to returning capital to shareholders, the Company intends to prioritize share repurchases as a use of the after-tax proceeds and repatriated cash following the closing of the transaction.

The agreements follow a comprehensive review of strategic alternatives for the China business, announced in July 2025. After evaluating a broad range of options, A. O. Smith's Board of Directors concluded that a strategic transaction with CPE is the best path forward for the China business, the Company and its shareholders. The transaction is expected to close in the first half of 2027, subject to regulatory approvals and other customary closing conditions. For the full release, click here.

Balance Sheet, Liquidity and Capital Allocation

As of September 30, 2026, cash balances totaled $234.5 million and debt totaled $673.1 million, resulting in a leverage ratio of 27.0% as measured by total debt-to-total capitalization. The increased leverage ratio compared to 2025 was due to cash borrowed under a new term loan used to acquire Leonard Valve in January 2026.

Cash provided by operations was $429.4 million in the first nine months of 2026, slightly lower than the same period in 2025. Free cash flow in the first nine months of 2026 increased 4% to $396.2 million, supported by lower capital expenditures of $33.2 million compared with $53.2 million in the prior year period. Higher non-cash expense adjustments and improved working capital offset lower earnings.

As part of its commitment to return capital to shareholders, the Company deployed $260.6 million to repurchase 4.2 million shares in the first nine months of 2026. As of September 30, 2026, authority remained to repurchase approximately 1.6 million additional shares. The Company projects its full-year 2026 share repurchases to total approximately $300 million.

On October 12, 2026, the Company's board of directors approved a 6% increase in the dividend rate, resulting in a five-year compound annual dividend growth rate of approximately 7%. The Company has increased its dividend for more than 30 consecutive years. For the full release, click here.

2026 Outlook

As a result of the announced sale of a majority interest in the China business, which represents a strategic shift in the Company's portfolio, the Company expects to classify the China business as held for sale and report it as discontinued operations beginning in the fourth quarter of 2026, with prior periods recast accordingly. Third quarter 2026 results presented in this release include the China business. Upon closing of the transaction, the Company expects to deconsolidate the China business and account for its retained 19% interest under the equity method. The Company will also review its segment reporting structure during the fourth quarter of 2026.

Accordingly, the Company has updated its full-year 2026 guidance to exclude the China business for all of 2026.

(in millions, except per share amounts)

Shafer concluded, "Our updated guidance reflects a more focused A. O. Smith, and our teams are committed to finishing the year strong. Looking ahead, we are excited about the opportunities in front of us, from our leading North American water heating and boiler franchise to our growth platforms in water treatment, water management and India. By concentrating on where we win, we are well positioned to drive profitable growth and create long-term value for our shareholders."

The Company's guidance also excludes the potential impact from future acquisitions.

A. O. Smith will host a webcasted conference call at 10:00 a.m. (Eastern Daylight Time) today. The call can be heard live on the Company's website click here. An audio replay of the call, along with the related presentation, will be available on the Company's website after the live event. To access the archived audio replay and related presentation, go to the "Investors" page and select the Third Quarter 2026 Earnings Call link.

To provide improved transparency into the operating results of its business, the Company is providing non-GAAP measures. Free cash flow is defined as cash provided by operations less capital expenditures. North America segment organic growth excludes the impact of Leonard Valve. Adjusted earnings, adjusted EPS, total segment earnings, adjusted segment earnings and adjusted segment margin exclude the impact of restructuring and impairment charges. Reconciliations from GAAP measures to non-GAAP measures are provided in the financial information included in this news release.

We provide guidance for net sales excluding China and adjusted EPS excluding China, which are non-GAAP financial measures, on a forward-looking basis.

Third Quarter Consolidated Revenues of $12.0 Billion*

Third Quarter GAAP Diluted EPS of $4.55* and Adjusted Diluted EPS of $6.06*

Net Income Attributable to Common Stock of $694.9 Million*

Adjusted EBITDA of $1.4 Billion*

Cash Flow From Operations of $1.5 Billion* and Free Cash Flow of $1.2 Billion*

Remaining Performance Obligations (RPO) of $41.8 Billion* and Total Backlog of $63.7 Billion*

Strong Performance Drives Significant Increase In 2026 Financial Expectations Across All Metrics

* = Record quarterly or record third quarter result

HOUSTON, Oct. 29, 2026 /PRNewswire/ -- Quanta Services, Inc. (NYSE: PWR) today announced results for the three months ended September 30, 2026. Revenues in the third quarter of 2026 were $12.01 billion compared to revenues of $7.63 billion in the third quarter of 2025, and net income attributable to common stock was $694.9 million, or $4.55 per diluted share, in the third quarter of 2026 compared to net income attributable to common stock of $339.4 million, or $2.24 per diluted share, in the third quarter of 2025. Adjusted diluted earnings per share attributable to common stock was $6.06 for the third quarter of 2026 compared to $3.33 for the third quarter of 2025.

"Quanta delivered another exceptional quarter, with third-quarter results that again exceeded expectations. Revenue, adjusted EBITDA and adjusted diluted earnings per share all achieved strong double-digit growth, cash flow was robust and total backlog reached a record $63.7 billion. These results demonstrate the power of our solutions-based operating model, as well as the execution certainty our self-perform capabilities deliver for customers every day. Given this outperformance and the expected incremental strength in the fourth quarter, we are again significantly increasing our full-year 2026 financial expectations across all metrics," said Duke Austin, President and Chief Executive Officer of Quanta Services.

"The breadth of our portfolio, combined with the fungibility of our skilled workforce across multiple end markets, provides a significant competitive advantage. This flexibility allows us to strategically deploy resources where demand is strongest, mitigate exposure to individual market cycles and deliver more consistent, predictable outcomes for our customers and stockholders. With demand for our services broadening across utility, power generation, industrial and technology customers, we are pacing ahead of the multi-year growth targets we outlined at our 2026 Investor Day, and our conviction in Quanta's ability to compound profitable growth over the long term continues to strengthen. We believe there is opportunity to deliver strong double-digit adjusted EPS growth in 2027, supported by continued backlog growth."

Certain items that impacted Quanta's results for the three and nine months ended September 30, 2026 and 2025 are reflected as adjustments in the calculation of Quanta's adjusted net income attributable to common stock, adjusted diluted earnings per share attributable to common stock and adjusted EBITDA (non-GAAP financial measures). These items are described in the accompanying tables reconciling adjusted net income attributable to common stock, EBITDA and adjusted EBITDA to net income attributable to common stock and adjusted diluted earnings per share attributable to common stock to diluted earnings per share attributable to common stock. Quanta completed five acquisitions in the first nine months of 2026 and eight acquisitions during the full year 2025, and the results of the acquired businesses are included in Quanta's consolidated results from the respective acquisition dates. For further information on the items that impacted comparability of 2026 and 2025, see the footnotes in the accompanying tables presenting Supplemental Segment Data and reconciliations of EBITDA, adjusted EBITDA, adjusted net income attributable to common stock and adjusted diluted earnings per share attributable to common stock (non-GAAP financial measures) to their comparable GAAP financial measures.

RECENT HIGHLIGHTS

- Completed Two Acquisitions - In September and October 2026, Quanta completed two acquisitions that strengthen its front-end, fabrication and supply chain capabilities. The first is a Houston, Texas-based energy services provider with approximately 320 employees that offers engineering and design, fabrication, automation and controls, and engineering, procurement and construction services, and is included in the Underground and Infrastructure segment. The second is a Fort Worth, Texas-based vertically integrated manufacturer of steel monopoles and lighting structures, primarily for utility transmission and distribution applications, with approximately 270 employees, which will primarily be included in the Electric segment. Aggregate consideration, net of cash acquired, was approximately $245 million, consisting of approximately $96 million in cash paid or payable and approximately $149 million in Quanta common stock. The two newly announced acquisitions are not expected to contribute materially to Quanta's full-year 2026 financial results.

- Enhanced Liquidity and Financial Flexibility - In August 2026, Quanta issued $2.00 billion aggregate principal amount of senior notes. In July 2026, Quanta increased the aggregate revolving commitments under its senior credit facility from $2.80 billion to $2.98 billion and extended the maturity date for revolving loans from July 31, 2030 to July 31, 2031. Effective August 8, 2026, Quanta increased the maximum amount of its unsecured commercial paper program from $2.80 billion to $2.98 billion. On September 1, 2026, Quanta prepaid the full $618.8 million outstanding balance of the term loan under its senior credit facility.

- Published 2025 Sustainability Report - In September 2026, Quanta published its 2025 Sustainability Report, which provides transparency around Quanta's sustainability strategy and the company's continued progress in 2025. Titled "Craft + Culture," the report highlights how Quanta's craft-skilled workforce and the investment in training, safety and leadership development behind it position the company to meet growing demand for reliable power, resilient infrastructure and modern energy systems.

- Appointed Ellen Rubin to Board of Directors - In September 2026, Ellen Rubin joined Quanta's Board of Directors. Ms. Rubin currently serves as an Operating Partner at Glasswing Ventures LLC, a venture capital firm focused on AI and frontier technologies, and as a director of Allegion plc. She brings executive leadership and public company board experience, as well as deep technology expertise, including AI and cloud computing innovation, technology strategy and cybersecurity risk management.

RESULTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026

Revenues in the nine months ended September 30, 2026 were $29.45 billion compared to revenues of $20.64 billion in the nine months ended September 30, 2025, and net income attributable to common stock was $1.37 billion, or $8.97 per diluted share, in the nine months ended September 30, 2026 compared to net income attributable to common stock of $712.9 million, or $4.72 per diluted share, in the nine months ended September 30, 2025. Adjusted diluted earnings per share attributable to common stock was $12.98 for the nine months ended September 30, 2026 compared to $7.59 for the nine months ended September 30, 2025.

FULL-YEAR 2026 OUTLOOK

Prior to the Company's conference call, management will post a summary of Quanta's updated 2026 guidance expectations with additional commentary in the "News and Events" and "Financial Info" areas of the Investor Relations section of Quanta's website at http://investors.quantaservices.com. 

The long-term outlook for Quanta's business is positive. However, weather, regulatory, permitting, supply chain challenges and other factors affecting project timing and execution have impacted, and may impact in the future, Quanta's financial results. Additionally, we continue to consider future uncertainty associated with overall challenges to the domestic and global economy, including inflation, interest rates and potential recessionary economic conditions. Quanta's financial outlook for revenues, margins and earnings reflects management's effort to align these uncertainties with the backlog the Company is executing on and the opportunities expected to materialize during the remainder of 2026.

The following forward-looking statements are based on current expectations, and actual results may differ materially, as described below in Cautionary Statement About Forward-Looking Statements and Information. For the full year ending December 31, 2026, Quanta now expects revenues to range between $41.3 billion and $41.6 billion and net income attributable to common stock to range between $1.92 billion and $1.98 billion. Quanta also now expects diluted earnings per share attributable to common stock to range between $12.57 and $12.97 and adjusted diluted earnings per share attributable to common stock to range between $17.90 and $18.30. Quanta now expects EBITDA to range between $3.99 billion and $4.09 billion and adjusted EBITDA to range between $4.40 billion and $4.49 billion. Additionally, for the full year ending December 31, 2026, Quanta now expects net cash provided by operating activities to range between $3.45 billion and $4.00 billion and free cash flow (a non-GAAP financial measure) to range between $2.50 billion and $3.00 billion.

NON-GAAP FINANCIAL MEASURES

The financial measures not prepared in conformity with generally accepted accounting principles in the United States (GAAP) that are utilized in this press release are provided to enable investors, analysts and management to evaluate Quanta's performance excluding the effects of certain items that management believes impact the comparability of operating results between reporting periods.

FORT LAUDERDALE, Fla., Oct. 29, 2026 /PRNewswire/ -- XTI Aerospace, Inc. (Nasdaq: XTIA) ("XTI Aerospace," "XTI," or the "Company"), an aerospace and advanced technology platform and parent company of Drone Nerds, LLC, ("Drone Nerds"), a leading drone solutions platform serving commercial, enterprise and government customers, today announced that it has reached a non-binding agreement to restructure and amend the terms of certain promissory notes issued on November 10, 2025 in connection with the acquisitions of Drone Nerds, LLC and Anzu Robotics, LLC (the "Seller Notes").

The Seller Notes, of which approximately $4.5 million in aggregate principal and capitalized interest remain outstanding, went into default on October 11, 2026. The restructured Seller Notes are expected to extend the maturity date and provide additional financial flexibility as the Company continues to execute on its restructuring strategy.

Under the non-binding term sheet, the Seller Notes will bear interest at a rate of 8.5% per annum, effective as of June 30, 2026, amortizing monthly over 60 months. Notwithstanding the foregoing, a balloon payment of all principal and accrued interest shall be payable on September 30, 2028. At any time during the first 12 months that the Seller Notes are outstanding, XTI shall have the option to elect to pay interest in kind ("PIK") until the Notes are paid in full.

In addition to the non-binding agreement to restructure and amend the terms of the Seller Notes, the Company continues to have constructive conversations regarding its revolving credit facility with JPMorgan Chase Bank, N.A., and is optimistic regarding the outcome of these discussions.

Additional details and provisions of the refinanced Seller Notes will be forthcoming once the documentation summarized in the Term Sheet is fully drafted and executed by the respective parties.

About XTI Aerospace, Inc.

XTI Aerospace, Inc. ("XTI") (Nasdaq: XTIA) is focused on building a leading platform for commercial and government drone adoption in the growing unmanned aircraft systems ("UAS") industry. Through its subsidiary, Drone Nerds, LLC, XTI supports enterprise and government customers in sectors including public safety, agriculture, construction, and energy across the drone program lifecycle, from hardware sourcing and deployment to training, service, repair, and the proprietary Always Flying⢠program. Its established U.S. customer base and reputation as a trusted solutions provider position the company as a go-to-market partner for drone manufacturers and software developers seeking to scale in the domestic market.

For more information about XTI, please visit xtiaerospace.com and follow XTI on LinkedIn, Instagram, X, and YouTube.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements.

Forward-looking statements may be identified by words such as "believe," "continue," "could," "would," "will," "expect," "intend," "plan," "target," "estimate," "project," or similar expressions. These statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such risks include, but are not limited to, the Company's ability to finalize and execute documentation to reflect the terms of the Term Sheet with the Seller Note holders, the ability to successfully negotiate and amend its asset-based credit facility with its lenders, the risk that its lender declines to make further advances or accelerates outstanding borrowings, substantial doubt about the Company's ability to continue as a going concern, the Company's ability to maintain the listing of its common stock on Nasdaq, the impact of Section 232 tariffs and other trade measures; pending regulatory inquiries and proceedings relating to the Company and its subsidiaries; potential conflicts of interest arising from its Interim Chief Executive Officer's economic interest in the holders of its acquisition-related notes, market adoption, regulatory requirements, supply chain conditions, technological development, integration of the acquired businesses, the Company's liquidity and ability to access additional capital on acceptable terms or at all, the Company's negative stockholders' equity and the sufficiency of its capital resources, and changes in applicable laws or regulations, customer demand variability and seasonal purchasing patterns, the Company's ability to achieve projected gross margins and operating cost reductions, working capital timing and inventory management, the outcome of pending legal proceedings involving the Company and its subsidiaries, the Company's ability to maintain relationships with key suppliers, restrictions and covenants under the Company's ABL credit facility, risks related to the wind-down of the Company's ADS division and the development of its ATM division, which has not generated revenues, and the potential for significant non-cash charges related to changes in the fair value of warrant liabilities as well as the other risks and uncertainties described in the Company's filings with the SEC. The Company's financial outlook and other projections in this press release are based on management's current expectations and assumptions and are particularly subject to these risks. XTI undertakes no obligation to update any forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law. Readers are encouraged to review the risk factors described in XTI's filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent filings.

Contacts:

General inquiries: 

Email: [email protected] 

Web: https://xtiaerospace.com/contact 

Investor Relations: 

[email protected] 

SOURCE XTI Aerospace, Inc.

Share this article

Unravel Biosciences is Astrosalva's founding development partner; Unravel co-founder and CEO Richard Novak, PhD, joins Astrosalva's board of directors

SAN MATEO, Calif., Oct. 29, 2026 /PRNewswire/ -- Astrosalva Therapeutics, Inc. ("Astrosalva"), a privately held, preclinical biotechnology company developing treatments for Alexander disease and the cerebral form of adrenoleukodystrophy (cALD), today announced its launch with Unravel Biosciences, Inc. ("Unravel") as its founding development partner. Richard Novak, PhD, co-founder and CEO of Unravel, has joined Astrosalva's board of directors. Families, clinicians and researchers can sign up for updates at astrosalva.com.

Alexander disease and the cerebral form of adrenoleukodystrophy (cALD) are rare genetic diseases that affect the brain's white matter. The cerebral form affects both children and adults, and in children it can progress rapidly, often leading to total disability within a few years. MedlinePlus puts the prevalence of X-linked adrenoleukodystrophy, the genetic condition behind cALD, at 1 in 15,000 people worldwide, and Ionis Pharmaceuticals estimates that Alexander disease affects about 1 in 1 to 3 million people worldwide. As Astrosalva learned more about the shared challenges faced by families affected by rare neurodegenerative diseases, it expanded its focus to cALD, where the need for new treatment options remains urgent.

"My son Max was seven months old when he was diagnosed with Alexander disease and we were told there was nothing that could be done," said Thomas Wagner, co-founder of Astrosalva. "I read hundreds of research papers and wrote to the scientists who had written them, and many wrote back. Those conversations showed me how much promise there is in the research. Astrosalva exists to turn it into medicines, for Max and for every family facing these diseases."

"Families living with Alexander disease and cALD now have approved treatments, and they still need more, including medicines that are easier to take," said Paul Schmidt, co-founder and CEO of Astrosalva. "After more than 10 years in rare disease, the pattern I keep seeing is promising research that never gets a company built around it. Thomas brought the science, and together we set up this company to turn it into a medicine, with the urgency these families deserve."

"Astrosalva embodies patient-led drug development, which is critical to meeting pressing patient needs," said Richard Novak, PhD, co-founder and CEO of Unravel. "We're pleased to be Astrosalva's founding development partner and bring our experience in rare and complex disease drug development to its programs."

Astrosalva's programs are preclinical, which means there is no active clinical trial or expanded-access program to join. Families, clinicians and researchers can write to [email protected], or sign up for updates at astrosalva.com.

About Astrosalva Therapeutics

Astrosalva Therapeutics is a privately held, preclinical biotechnology company developing treatments for Alexander disease and the cerebral form of adrenoleukodystrophy (cALD). Astrosalva was co-founded by Thomas Wagner and Paul Schmidt. Unravel Biosciences, a clinical-stage therapeutics company, is its founding development partner. Paul Schmidt, the company's chief executive officer, has spent nearly 15 years in biopharma, more than 10 of them in rare disease. The company is based in San Mateo, California.

About Unravel Biosciences

Unravel is a clinical-stage therapeutics company that integrates AI systems biology computation with rapid clinical validation of discovered targets. Its proprietary Predictable Medicine⢠platform uses primary transcriptomics data to create Living Molecular Twins⢠of real patients that can be used to predict therapeutic response. Unravel's platform-discovered therapeutic pipeline spans neurodegenerative, neurodevelopmental, and metabolic disorders.

Media contact

Astrosalva Therapeutics: [email protected]

Unravel Biosciences: [email protected]

SOURCE Astrosalva Therapeutics, Inc.

Share this article

- Co-Founder, CEO Sulagna Bhattacharya to join Keynote Panel on navigating the cell and gene therapy landscape and driving market success

- Co-Founder, President Samarendra Mohanty, PhD, to present on disease-agnostic gene therapy for neurodegenerative conditions

- EVP, Value & Access Ramesh Arjunji to present on building early evidence to support access and pricing for rare diseases and joining panel on expanding access to cell and gene therapies

- Sessions to address scientific, commercial, and market access path for MOGENRY® (sonpiretigene isteparvovec; MCO-010), a one-tme, in-office, mutation-agnostic, optogenetic gene therapy currently under FDA and PMDA review

DALLAS, Oct. 29, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that members of its leadership team will participate in Advanced Therapies USA 2026, taking place November 4â5, 2026, at the Hynes Convention Center in Boston, Massachusetts. Sulagna Bhattacharya, Co-Founder and Chief Executive Officer, will join the conference's Keynote Panel Discussion, "Navigating the Cell and Gene Therapy Landscape: Opportunities & Challenges for Driving Market Success." Samarendra Mohanty, PhD, Co-Founder, President and Chief Scientific Officer, will present "Disease-Agnostic Gene Therapy for Neurodegenerative Conditions" in the conference's Gene Therapy track, and Ramesh Arjunji, Executive Vice President, Value & Access, will present "Starting Early to Develop Evidence to Support Access & Pricing for Rare Diseases" and join the panel discussion "Overcoming Barriers and Expanding Access to Cell and Gene Therapies," both in the Evidence, Pricing & Access track. Advanced Therapies USA convenes cell and gene therapy developers, manufacturers, investors, and commercial leaders to address the challenges of bringing advanced therapies from the clinic to patients.

Presentation Details:

Advanced Therapies USA 2026, Hynes Convention Center, Boston, Massachusetts

Session: Navigating the Cell and Gene Therapy Landscape: Opportunities & Challenges for Driving Market Success

Format: Keynote Panel Discussion

Moderator: Miguel Forte, CEO, Kiji Therapeutics, and President, International Society for Cell & Gene Therapy (ISCT)

Panelist: Sulagna Bhattacharya, MBA, Co-Founder and Chief Executive Officer

Date & Time: Wednesday, November 4, 2026, 9:45 AM ET

Location: Keynote/Theatre 1

Session: Disease-Agnostic Gene Therapy for Neurodegenerative Conditions

Format: Presentation

Track: Gene Therapy (Track 4)

Presenter: Samarendra Mohanty, PhD, Co-Founder, President and Chief Scientific Officer

Date & Time: Wednesday, November 4, 2026, 11:30 AM ET

Location: Hall D, Level 2

Session: Starting Early to Develop Evidence to Support Access & Pricing for Rare Diseases

Format: Presentation

Track: Evidence, Pricing & Access (Track 8)

Presenter: Ramesh Arjunji, PhD, Executive Vice President, Value & Access

Date & Time: Wednesday, November 4, 2026, 1:55 PM ET

Location: Room 209

Session: Overcoming Barriers and Expanding Access to Cell and Gene Therapies

Format: Panel Discussion

Track: Evidence, Pricing & Access (Track 8)

Moderator: Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)

Panelist: Ramesh Arjunji, Executive Vice President, Value & Access

Date & Time: Wednesday, November 4, 2026, 5:10 PM ET

Location: Room 209

Session: Where's the Money? Evolution And Future Outlook for Investment in Advanced Therapies

Format: Keynote Panel Discussion

Moderator: Sven Kili, Partner, Saisei Ventures

Panelist: Samarendra Mohanty, PhD, Co-Founder and President

Date & Time: Thursday, November 5, 2026, 9:35 AM ET

Location: Keynote/Theatre 1

Session: Navigating Global Regulatory Filings

Format: Presentation

Speaker: Ananta Ayagari, PhD, Sr. Director of Regulatory

Date & Time: Wednesday, November 5, 2026, 4:20 PM ET

Location: Room 209

During the keynote panel, Ms. Bhattacharya will join moderator Miguel Forte and executives from KSQ Therapeutics, Aleko Therapeutics, Iovance Biotherapeutics, Orchard Therapeutics, and Sumitomo Pharma America to discuss the opportunities and challenges of driving market success for cell and gene therapies, drawing on Nanoscope's progress toward potential global approval of its lead asset, MOGENRY® (sonpiretigene isteparvovec; MCO-010), for the treatment of inherited retinal dystrophies, including the status of the Company's Biologics License Application (BLA), and Japan New Drug Application (JNDA), currently under FDA and PMDA review, respectively. In his Gene Therapy track presentation, Dr. Mohanty, who invented Nanoscope's multi-characteristic opsin (MCO) platform, will discuss how delivering a light-sensitive opsin to surviving bipolar cells enables a mutation-agnostic approach to restoring vision lost to retinal neurodegeneration, without the need for genetic testing, invasive surgery, or repeat dosing. In the Evidence, Pricing & Access track, Mr. Arjunji will discuss why rare disease developers should begin generating evidence early in development to support market access and pricing, drawing on Nanoscope's approach to preparing MOGENRY for potential launch. Later that day, he will join a panel moderated by Nneka Onwudiwe, former PRO/PE Regulatory Review Officer at the FDA, alongside leaders from AIVITA Biomedical, Tolerance Bio, the Oklahoma Health Care Authority, the Emily Whitehead Foundation, and HebeCell Corporation, to discuss overcoming barriers and expanding patient access to cell and gene therapies. Members of the Nanoscope leadership team will be available to meet with potential partners, investors, and industry stakeholders throughout the conference.

About MOGENRY (sonpiretigene isteparvovec; MCO-010)

Nanoscope's multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope's Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team has spent over a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope's MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows. MOGENRY is under review by the FDA for the treatment of RP with severe vision loss and under priority review by the PMDA and MHLW for the treatment of IRDs in Japan.

About Nanoscope Therapeutics

Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the FDA has accepted and filed the Company's BLA for MOGENRY, and the PMDA has accepted for priority review the Company's NDA for MOGENRY for the treatment of IRDs in Japan. If approved, MOGENRY has the potential to become the standard of care for patients with RP and other IRDs, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with RMAT designation for SD, and EMA Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for inherited retinal dystrophies (IRDs) in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to start in 2026, and other IND-ready programs include Leber congenital amaurosis (LCA). Learn more at NanosTherapeutics.com and follow @NSTherapeutics on X and on LinkedIn.

Contact:

Nanoscope Therapeutics, Inc

+1 (817) 857-1186

[email protected]

SOURCE Nanoscope Therapeutics

Share this article

BCBSOK offers coverage in all 77 Oklahoma counties, along with new plan choices and wellness rewards for 2027

TULSA, Okla., Oct. 29, 2026 /PRNewswire/ -- As Open Enrollment begins Nov. 1, Blue Cross and Blue Shield of Oklahoma (BCBSOK) is helping Oklahomans navigate their 2027 health coverage options and understand what to consider when choosing a plan.

When comparing plans, the monthly premium is only one part of the decision. Consumers should also consider whether their preferred doctors and hospitals are in-network, how often they expect to use health care, and what they could pay through deductibles, copays and other out-of-pocket costs.

"Our commitment to Oklahoma extends across the state, from our largest cities to our rural communities," said Stephania Grober, President of BCBSOK. "We remain focused on providing individuals and families throughout Oklahoma with access to quality coverage and care."

2027 Plan Highlights

BCBSOK will offer individual and family health plan options for 2027, including:

- Statewide coverage options: Blue Advantage PPOSM will continue to be available across all 77 Oklahoma counties, with a network that includes approximately 125 hospitals and 27,019 providers.

- MyBlue HMOSM: Available in 15 Oklahoma counties, with a network that includes approximately 47 hospitals and 15,198 providers.

- Additional coverage choices: For 2027, BCBSOK is adding catastrophic plan options to both MyBlue HMO and Blue Advantage PPO. BCBSOK is also transitioning Blue Preferred PPO to an off-exchange-only network.

- New wellness rewards: GO WellbeingSM and Go Points will allow eligible members age 18 and older to earn up to $100 each year for participating in certain healthy activities.

What to Consider When Choosing a Plan

As Oklahomans compare their options for 2027, BCBSOK encourages consumers to consider:

- Provider network: Are your preferred doctors, specialists and hospitals in-network?

- Health care needs: How often do you expect to visit a doctor, fill prescriptions or need other care?

- Total costs: Consider how monthly premiums and out-of-pocket costs fit your budget and expected health care needs.

- Plan type: Understand how each plan works and what it means for where and how you receive care.

- Additional benefits: Consider programs and resources that can help support your health throughout the year.

Marketplace Open Enrollment runs from Nov. 1, 2026, through Jan. 15, 2027. Oklahomans who enroll by Dec. 15 can have coverage beginning Jan. 1, 2027. To learn more about BCBSOK individual and family health plan options, visit MyCardBCBSOK.com or call 888-900-4384. Additional assistance is available through an independent, authorized agent.

About Blue Cross and Blue Shield of Oklahoma: For more than 85 years, Blue Cross and Blue Shield of Oklahoma has been committed to meeting the health care financing needs of Oklahomans. As the state's oldest and largest customer-owned health insurer, Blue Cross and Blue Shield of Oklahoma provides health care benefit plans for more than 810,000 Oklahomans. Blue Cross and Blue Shield of Oklahoma is a division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association.

SOURCE Blue Cross and Blue Shield of Oklahoma

Share this article